NCT01000883招募中不适用
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10,000
- 试验地点
- 2
- 主要终点
- Generation of a biorepository for current and future correlative research studies
研究概览
简要总结
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tissue and blood samples from women with locally advanced or metastatic breast cancer
详细描述
OBJECTIVES:
- Collect , catalogue, and store biological specimens from patients with locally advanced or metastatic breast cancer
- To collect clinical data from these patients containing identifiers, demographics, epidemiologic review, clinical evaluation, treatment, and long-term follow-up.
- To provide an efficient bi-directional flow of clinical information and specimens between laboratory and clinical scientists in order to foster innovative translational research.
OUTLINE: This is a multicenter study.
Patients undergo core biopsy and blood sampling at diagnosis, between chemotherapy regimens, and prior to definitive surgery. Tumor markers are assessed using immunohistochemistry and flow cytometry.
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High suspicion of or known breast cancer (early or metastatic)
- •Lesion accessible for safe biopsy (as deemed by the treating physician).
- •Age ≥ 18 years.
- •ECOG performance status 0 -
- •Ability to understand and willingness to sign an informed consent document.
- •If receiving therapeutic anticoagulation; it should be discontinued temporarily prior to biopsy for a length of time to be determined by the study doctor.
- •Adequate marrow function, defined as absolute neutrophil count ≥ 1.5 x 109/L and platelets ≥ 100 x 109/L required only for biopsies of vital organs (lung, liver, etc.)
排除标准
- •Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety.
- •Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- •History of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine)
- •Pregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of conscious sedation, which is required for biopsies of certain anatomic sites (e.g. liver, lung). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.
- •Cardiac disease making it unsafe to biopsy in the opinion of the treating physician.
- •If patients receiving bevacizumab or other angiogenesis inhibitors are less than 6 weeks from last dose of the angiogenesis inhibitor, they should not undergo research core biopsies of vital organs (lung, liver, etc.) on this protocol because of the concern for the possibility of increased bleeding risk and delayed healing. Patients receiving bevacizumab or other angiogenesis inhibitors who are undergoing a research biopsy of the breast, peripheral lymph node or a skin punch biopsy must be two weeks from the last dose of the angiogenesis inhibitor.
结局指标
主要结局
Generation of a biorepository for current and future correlative research studies
时间窗: Diagnosis, between treatments,7-14 days after start of treatment and at time of definitive therapy
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and ChemotherapyColorectal CancerNCT00918827Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan2,128
撤回
不适用
Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for CancerHematopoietic/Lymphoid CancerUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol SpecificNCT00899808Rutgers, The State University of New Jersey
已完成
4 期
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal CancerColorectal CancerNCT00559676Centre Hospital Regional Universitaire de Limoges200
已完成
不适用
Study of Tissue and Blood Samples From Patients With High-Grade GliomaBrain and Central Nervous System TumorsNCT01004887Alliance for Clinical Trials in Oncology631
Unknown
不适用
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17Breast CancerNCT00897065Massachusetts General Hospital957